ReferencesPrescribing InformationPrivacy  

WinRho SDF® (Rho(D) Immune Globulin Intravenous (Human)) Program #1

  1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
  2. Prelone syrup [Package Insert]. Tewksbury, Massachusetts: Muro Pharmaceuticals, Inc; January 1999.
  3. WinRho SDF® [Package Insert]. Winnipeg, Canada: Cangene Corporation; February 2002.
  4. Gammagard S/D® [Package Insert]. Glendale, California: Baxter Healthcare Corp; 2001.
  5. Bell WB, Jr. Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura. Semin Hematol. 2000;37(Suppl 1):22-25.
  6. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol. 2001;54:214-218.
  7. Cooper N, Woloski BMR, Fodero EM, et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood. 2002;99:1922-1927.
  8. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991;77:1884-1893.
  9. Nabi Biopharmaceuticals. Data on file.
  10. Simpson KN, Coughlin EM, Eron J, Bussel JB. Idiopathic thrombocytopenic purpura: treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. Semin Hematol. 1998;35(Suppl 1):58-64.
  11. Sandler SG, Novak SC, Roland B. The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin. Am J Hematol. 2000;63:156-158.